Ignite Creation Date:
2024-05-05 @ 9:09 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00828282
Status:
COMPLETED
Last Update Posted:
2014-05-26
First Post:
2009-01-22
Brief Title:
High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL
Sponsor:
John Haslip
Organization:
University of Kentucky
Study Overview
Official Title:
High-dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL Pilot Trial and Pharmacokinetic-pharmacodynamic Studies
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary aim of this trial is to generate a preliminary analysis of this novel therapeutic approach and laboratory studies for patients with recurrent or refractory CLL Further this pilot trial will demonstrate the feasibility of the translational science methods proposed for this new collaboration of investigators The investigators hypothesize that patients with relapsed CLL are recruitable to this study that the methods for measuring simvastatin concentration and target protein translation are feasible and that the investigators can efficiently apply the laboratory research methods to patient blood samples before and after patients have taken the study medication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None